Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Monocyte-derived dendritic cells from chronic myeloid leukaemia have abnormal maturation and cytoskeletal function that is associated with defective localisation and signalling by normal ABL1 protein.

Brown S, Hutchinson CV, Aspinall-O'Dea M, Whetton AD, Johnson SM, Rees-Unwin K, Burthem J.

Eur J Haematol. 2014 Aug;93(2):96-102. doi: 10.1111/ejh.12306. Epub 2014 Apr 10.

PMID:
24617663
2.

Detection in primary chronic myeloid leukaemia cells of p210BCR-ABL1 in complexes with adaptor proteins CBL, CRKL, and GRB2.

Patel H, Marley SB, Gordon MY.

Genes Chromosomes Cancer. 2006 Dec;45(12):1121-9.

PMID:
16955467
3.

Plasma tyrosine kinase activity as a potential biomarker in BCR-ABL1-targeted therapy.

Yeh CH, Abdool A, Bruey JM.

Cancer Biomark. 2010;7(6):295-303. doi: 10.3233/CBM-2010-0193.

PMID:
21694468
4.

Induced dendritic cell differentiation of chronic myeloid leukemia blasts is associated with down-regulation of BCR-ABL.

Lindner I, Kharfan-Dabaja MA, Ayala E, Kolonias D, Carlson LM, Beazer-Barclay Y, Scherf U, Hnatyszyn JH, Lee KP.

J Immunol. 2003 Aug 15;171(4):1780-91.

5.

Molecular biology of chronic myeloid leukemia.

Maru Y.

Int J Hematol. 2001 Apr;73(3):308-22. Review.

PMID:
11345196
6.

Deregulation of the Wilms' tumour gene 1 protein (WT1) by BCR/ABL1 mediates resistance to imatinib in human leukaemia cells.

Svensson E, Vidovic K, Lassen C, Richter J, Olofsson T, Fioretos T, Gullberg U.

Leukemia. 2007 Dec;21(12):2485-94. Epub 2007 Aug 30.

PMID:
17728783
7.

BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia.

Leo E, Mancini M, Aluigi M, Luatti S, Castagnetti F, Testoni N, Soverini S, Santucci MA, Martinelli G.

PLoS One. 2013 Dec 10;8(12):e81425. doi: 10.1371/journal.pone.0081425. eCollection 2013.

8.

Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives.

Borgo C, Cesaro L, Salizzato V, Ruzzene M, Massimino ML, Pinna LA, Donella-Deana A.

Mol Oncol. 2013 Dec;7(6):1103-15. doi: 10.1016/j.molonc.2013.08.006. Epub 2013 Aug 22.

9.

Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration.

Dong R, Cwynarski K, Entwistle A, Marelli-Berg F, Dazzi F, Simpson E, Goldman JM, Melo JV, Lechler RI, Bellantuono I, Ridley A, Lombardi G.

Blood. 2003 May 1;101(9):3560-7. Epub 2002 Dec 27.

10.

Expression of BCR-ABL1 oncogene relative to ABL1 gene changes overtime in chronic myeloid leukemia.

Gupta M, Milani L, Hermansson M, Simonsson B, Markevärn B, Syvänen AC, Barbany G.

Biochem Biophys Res Commun. 2008 Feb 15;366(3):848-51. Epub 2007 Dec 17.

PMID:
18082628
11.

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene.

Sharma N, Magistroni V, Piazza R, Citterio S, Mezzatesta C, Khandelwal P, Pirola A, Gambacorti-Passerini C.

Mol Cancer. 2015 Jul 16;14:132. doi: 10.1186/s12943-015-0407-0.

12.

BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients.

Marega M, Piazza RG, Pirola A, Redaelli S, Mogavero A, Iacobucci I, Meneghetti I, Parma M, Pogliani EM, Gambacorti-Passerini C.

Leukemia. 2010 Aug;24(8):1445-9. doi: 10.1038/leu.2010.101. Epub 2010 Jun 3.

PMID:
20520635
13.

Engagement of the CrkL adaptor in interferon alpha signalling in BCR-ABL-expressing cells.

Grumbach IM, Mayer IA, Uddin S, Lekmine F, Majchrzak B, Yamauchi H, Fujita S, Druker B, Fish EN, Platanias LC.

Br J Haematol. 2001 Feb;112(2):327-36.

PMID:
11167825
14.

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.

Hamilton A, Helgason GV, Schemionek M, Zhang B, Myssina S, Allan EK, Nicolini FE, Müller-Tidow C, Bhatia R, Brunton VG, Koschmieder S, Holyoake TL.

Blood. 2012 Feb 9;119(6):1501-10. doi: 10.1182/blood-2010-12-326843. Epub 2011 Dec 19.

15.

BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia.

Roy S, Jørgensen HG, Roy P, Abed El Baky M, Melo JV, Strathdee G, Holyoake TL, Bartholomew C.

Br J Haematol. 2012 May;157(4):446-56. doi: 10.1111/j.1365-2141.2012.09078.x. Epub 2012 Feb 29.

PMID:
22372463
16.

The Bcr-Abl kinase regulates the actin cytoskeleton via a GADS/Slp-76/Nck1 adaptor protein pathway.

Preisinger C, Kolch W.

Cell Signal. 2010 May;22(5):848-56. doi: 10.1016/j.cellsig.2009.12.012. Epub 2010 Jan 14.

PMID:
20079431
17.

Gene expression analysis of BCR/ABL1-dependent transcriptional response reveals enrichment for genes involved in negative feedback regulation.

Håkansson P, Nilsson B, Andersson A, Lassen C, Gullberg U, Fioretos T.

Genes Chromosomes Cancer. 2008 Apr;47(4):267-75. doi: 10.1002/gcc.20528.

PMID:
18181176
18.

Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.

Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, Wong A, Pattacini L, Goldman JM, Melo JV.

Cancer Res. 2005 Oct 1;65(19):8912-9.

19.

Differentiation of acute and chronic myeloid leukemic blasts into the dendritic cell lineage: analysis of various differentiation-inducing signals.

Kharfan-Dabaja M, Ayala E, Lindner I, Cejas PJ, Bahlis NJ, Kolonias D, Carlson LM, Lee KP.

Cancer Immunol Immunother. 2005 Jan;54(1):25-36.

PMID:
15693136
20.

p210(Bcr-Abl) desensitizes Cdc42 GTPase signaling for SDF-1alpha-directed migration in chronic myeloid leukemia cells.

Chang YC, Tien SC, Tien HF, Zhang H, Bokoch GM, Chang ZF.

Oncogene. 2009 Nov 19;28(46):4105-15. doi: 10.1038/onc.2009.260. Epub 2009 Aug 31.

PMID:
19718053
Items per page

Supplemental Content

Write to the Help Desk